Cargando…

Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy

Tenofovir and entecavir are currently designated as the preferred oral antiviral drugs for chronic hepatitis B. However, only less than 40% of patients can achieve HBeAg seroconversion. We aim at investigating the role of intestinal microbiome in HBeAg seroconversion induced by oral antiviral therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Yu-Li, Qin, Lei, Wei, Wen-Jun, Cai, Hong, Yu, Xiao-Fang, Zhang, Wei, Wu, Xiao-Lu, Liu, Xiao-Bin, Chen, Wei-Ming, You, Pan, Hong, Mei-Zhu, Liu, Yaming, Dong, Xuan, Shia, Ben-Chang, Niu, Jian-Jun, Pan, Jin-Shui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864979/
https://www.ncbi.nlm.nih.gov/pubmed/33547384
http://dx.doi.org/10.1038/s41598-021-82939-1
_version_ 1783647754789060608
author Zeng, Yu-Li
Qin, Lei
Wei, Wen-Jun
Cai, Hong
Yu, Xiao-Fang
Zhang, Wei
Wu, Xiao-Lu
Liu, Xiao-Bin
Chen, Wei-Ming
You, Pan
Hong, Mei-Zhu
Liu, Yaming
Dong, Xuan
Shia, Ben-Chang
Niu, Jian-Jun
Pan, Jin-Shui
author_facet Zeng, Yu-Li
Qin, Lei
Wei, Wen-Jun
Cai, Hong
Yu, Xiao-Fang
Zhang, Wei
Wu, Xiao-Lu
Liu, Xiao-Bin
Chen, Wei-Ming
You, Pan
Hong, Mei-Zhu
Liu, Yaming
Dong, Xuan
Shia, Ben-Chang
Niu, Jian-Jun
Pan, Jin-Shui
author_sort Zeng, Yu-Li
collection PubMed
description Tenofovir and entecavir are currently designated as the preferred oral antiviral drugs for chronic hepatitis B. However, only less than 40% of patients can achieve HBeAg seroconversion. We aim at investigating the role of intestinal microbiome in HBeAg seroconversion induced by oral antiviral therapy and describe multi-omics characteristics of HBeAg seroconversion associated intestinal flora. In this study, we prospectively collected fecal samples at baseline from the patients with HBeAg positive chronic hepatitis B who would have oral antiviral therapy. 16S rDNA sequencing and metabolomics were performed. We identified HBeAg seroconversion-related microbial signature and constructed prediction model for HBeAg seroconversion. Thirty-seven of these subjects achieved HBeAg seroconversion within 156 weeks after the initiation of oral antiviral therapy, while 41 subjects remained HBeAg positive even after over 156 weeks of therapy. A computational statistical and machine learning approach allowed us to identify a microbial signature for HBeAg seroconversion. Using random forest method, we further constructed a classifier based on the microbial signature, with area under curve being 0.749 for the test set. Patients who achieved HBeAg seroconversion tended to have lower abundance of certain fecal metabolites such as essential amino acids, and several dipeptides. By analyzing the fecal microbiota from the patients with and without HBeAg seroconversion, we showed intestinal microbiome play a critical role in HBeAg seroconversion induced by oral antiviral therapy. We also identified intestinal microbial signature that is associated with HBeAg seroconversion after oral antiviral therapy.
format Online
Article
Text
id pubmed-7864979
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78649792021-02-08 Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy Zeng, Yu-Li Qin, Lei Wei, Wen-Jun Cai, Hong Yu, Xiao-Fang Zhang, Wei Wu, Xiao-Lu Liu, Xiao-Bin Chen, Wei-Ming You, Pan Hong, Mei-Zhu Liu, Yaming Dong, Xuan Shia, Ben-Chang Niu, Jian-Jun Pan, Jin-Shui Sci Rep Article Tenofovir and entecavir are currently designated as the preferred oral antiviral drugs for chronic hepatitis B. However, only less than 40% of patients can achieve HBeAg seroconversion. We aim at investigating the role of intestinal microbiome in HBeAg seroconversion induced by oral antiviral therapy and describe multi-omics characteristics of HBeAg seroconversion associated intestinal flora. In this study, we prospectively collected fecal samples at baseline from the patients with HBeAg positive chronic hepatitis B who would have oral antiviral therapy. 16S rDNA sequencing and metabolomics were performed. We identified HBeAg seroconversion-related microbial signature and constructed prediction model for HBeAg seroconversion. Thirty-seven of these subjects achieved HBeAg seroconversion within 156 weeks after the initiation of oral antiviral therapy, while 41 subjects remained HBeAg positive even after over 156 weeks of therapy. A computational statistical and machine learning approach allowed us to identify a microbial signature for HBeAg seroconversion. Using random forest method, we further constructed a classifier based on the microbial signature, with area under curve being 0.749 for the test set. Patients who achieved HBeAg seroconversion tended to have lower abundance of certain fecal metabolites such as essential amino acids, and several dipeptides. By analyzing the fecal microbiota from the patients with and without HBeAg seroconversion, we showed intestinal microbiome play a critical role in HBeAg seroconversion induced by oral antiviral therapy. We also identified intestinal microbial signature that is associated with HBeAg seroconversion after oral antiviral therapy. Nature Publishing Group UK 2021-02-05 /pmc/articles/PMC7864979/ /pubmed/33547384 http://dx.doi.org/10.1038/s41598-021-82939-1 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Zeng, Yu-Li
Qin, Lei
Wei, Wen-Jun
Cai, Hong
Yu, Xiao-Fang
Zhang, Wei
Wu, Xiao-Lu
Liu, Xiao-Bin
Chen, Wei-Ming
You, Pan
Hong, Mei-Zhu
Liu, Yaming
Dong, Xuan
Shia, Ben-Chang
Niu, Jian-Jun
Pan, Jin-Shui
Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
title Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
title_full Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
title_fullStr Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
title_full_unstemmed Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
title_short Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
title_sort meta-omics characteristics of intestinal microbiota associated to hbeag seroconversion induced by oral antiviral therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7864979/
https://www.ncbi.nlm.nih.gov/pubmed/33547384
http://dx.doi.org/10.1038/s41598-021-82939-1
work_keys_str_mv AT zengyuli metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT qinlei metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT weiwenjun metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT caihong metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT yuxiaofang metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT zhangwei metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT wuxiaolu metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT liuxiaobin metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT chenweiming metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT youpan metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT hongmeizhu metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT liuyaming metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT dongxuan metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT shiabenchang metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT niujianjun metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy
AT panjinshui metaomicscharacteristicsofintestinalmicrobiotaassociatedtohbeagseroconversioninducedbyoralantiviraltherapy